FDA advisors endorse Eli Lilly’s Alzheimer’s drug

An advisory panel to the FDA recommended Eli Lilly’s Alzheimer’s drug donanemab on Monday, potentially paving the way for its full approval in the US later this year.

If approved, donanemab w…